Chauhan and co-workers demonstrated that Hsp27 can promote the survival of malignant tumours by conferring resistance to the inflammatory drug dexamethasone (a drug for treating HIDs such as rheumatoid arthritis, skin inflammation, and cancer) in myeloma cell lines via the inhibition of SMAC (mitochondrial release of second mitochondrial-derived activator of caspases) and cytochrome c, both of which are masters of intrinsic apoptosis mediators [138]. The gene discussed is CYCS; the disease is plasma cell myeloma.